Autolus Therapeutics
About Autolus Therapeutics
Autolus is a London-based clinical-stage biopharma developing next-generation programmed T-cell (CAR-T) therapies for cancer.
Milestones
Milestones as listed on autolus.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on autolus.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Products & Services
Products and services as listed on autolus.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Obe-cel
Lead CAR T cell therapy, being investigated in ongoing oncology and autoimmune disease studies.
Source: autolus.comObe-cel in SLE
Phase 1 study of obe-cel in refractory systemic lupus erythematosus.
Source: autolus.comAUTO1/22
Dual-targeting CD19/CD22 CAR T candidate built on obe-cel.
Source: autolus.comAUTO4 and AUTO5
Programmed T cell therapies for peripheral T-cell lymphoma targeting TRBC1 and TRBC2.
Source: autolus.comAUTO6NG
GD2-targeting programmed T cell therapy for neuroblastoma and other GD2-expressing solid tumours.
Source: autolus.comAUTO8
Next-generation dual-CAR candidate for multiple myeloma targeting BCMA and CD19.
Source: autolus.comPipeline & Regulatory Record
What public registers list for Autolus Therapeutics: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 10 Oct 2026.
Clinical trials 6 in our ClinicalTrials.gov registers · 1 in the EU register
All trials by sponsor name 1 registry name
Drugs in these trials 2 compounds
EU trials register (CTIS) 1 authorised or ongoing
- A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY TO DETERMINE THE SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PARTICIPANTS WITH SEVERE, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS WITH ACTIVE LUPUS NEPHRITIS2024-519941-32-00 · Phase II · Authorised
Group (Autolus Therapeutics): founded 2014, website autolus.com. Wikidata Q56583577. From Wikidata (CC0), matched by the group's Legal Entity Identifier.
How this is matched: register records are linked to this page by the organisation name they carry, here Autolus Limited; Autolus GmbH. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports Autolus Therapeutics plc files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $75.4m | $118m | 156.1% | −$288m | 10-K 2026 |
| Dec 2024 | $10.1m | $138m | >999% | −$221m | 10-K 2025 |
| Dec 2023 | $1.7m | $130m | >999% | −$208m | 10-K 2025 |
| Dec 2019 | $2.9m | $105m | >999% | −$124m | 20-F 2020 |
| Sep 2018 | $1.4m | $36.2m | >999% | −$44.8m | 20-F 2020 |
Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.